Free Trial

Verici Dx (VRCI) Competitors

Verici Dx logo
GBX 3.28
-0.23 (-6.43%)
(As of 11/1/2024 12:39 PM ET)

VRCI vs. AGL, YGEN, ABDX, GDR, PRM, GENI, IDHC, LLAI, DMTR, and LLA

Should you be buying Verici Dx stock or one of its competitors? The main competitors of Verici Dx include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), genedrive (GDR), Proteome Sciences (PRM), GENinCode (GENI), Integrated Diagnostics (IDHC), LungLife AI (LLAI), Deepmatter Group (DMTR), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.

Verici Dx vs.

ANGLE (LON:AGL) and Verici Dx (LON:VRCI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

ANGLE has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Verici Dx has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Verici Dx has higher revenue and earnings than ANGLE. Verici Dx is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.02M12.37-£18.03M-£0.07-110.71
Verici Dx£4.33M1.83-£4.81M-£0.02-163.75

ANGLE received 182 more outperform votes than Verici Dx when rated by MarketBeat users.

CompanyUnderperformOutperform
ANGLEOutperform Votes
182
62.33%
Underperform Votes
110
37.67%
Verici DxN/AN/A

18.8% of ANGLE shares are held by institutional investors. Comparatively, 51.9% of Verici Dx shares are held by institutional investors. 16.2% of ANGLE shares are held by company insiders. Comparatively, 17.1% of Verici Dx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ANGLE currently has a consensus price target of GBX 70, indicating a potential upside of 803.23%. Given ANGLE's higher possible upside, equities analysts clearly believe ANGLE is more favorable than Verici Dx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verici Dx
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

ANGLE has a net margin of 0.00% compared to Verici Dx's net margin of -110.99%. Verici Dx's return on equity of -58.12% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLEN/A -63.75% -29.89%
Verici Dx -110.99%-58.12%-26.14%

In the previous week, ANGLE's average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.

Company Overall Sentiment
ANGLE Neutral
Verici Dx Neutral

Summary

Verici Dx beats ANGLE on 8 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRCI vs. The Competition

MetricVerici DxDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£7.94M£17.51M£5.41B£1.60B
Dividend YieldN/A6.10%5.15%10.93%
P/E Ratio-163.752.18113.591,755.31
Price / Sales1.832,474.421,480.95232,682.53
Price / Cash1.314.6039.8336.19
Price / Book0.822.764.642.88
Net Income-£4.81M£59.41M£119.13M£145.32M
7 Day Performance-6.43%-1.47%0.78%0.11%
1 Month Performance-49.62%-7.57%5.66%-0.11%
1 Year Performance-51.48%18.67%36.85%15.48%

Verici Dx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRCI
Verici Dx
N/AGBX 3.28
-6.4%
N/A-49.8%£7.94M£4.33M-163.7519
AGL
ANGLE
1.6739 of 5 stars
GBX 7.25
-6.5%
GBX 70
+865.5%
-33.8%£23.38M£2.02M-103.57650
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 8.25
flat
N/A-21.2%£15.64M£6.13M-899.0084Gap Down
GDR
genedrive
N/AGBX 2.23
+0.9%
N/A-71.0%£12.09M£49,000.00-55.6343News Coverage
Gap Up
PRM
Proteome Sciences
N/AGBX 2.52
-10.0%
N/A-55.8%£7.44M£4.04M-252.00240Gap Up
GENI
GENinCode
N/AGBX 4.10
flat
N/A-46.8%£7.26M£2.60M-82.002,300
IDHC
Integrated Diagnostics
N/AGBX 0.50
+4.2%
N/A+37.8%£2.88M£4.75B16.506,692
LLAI
LungLife AI
N/AGBX 9
-10.0%
N/A-91.0%£2.76M£98,566.00-69.2315Gap Down
DMTR
Deepmatter Group
N/AGBX 0.03
+22.2%
N/A+0.0%£1.33M£1.04M-0.11N/AGap Down
LLA
LLA.L,0P0001T9GN,0
N/AGBX 15
-25.0%
N/AN/A£0.00N/A-125.0015Gap Down
High Trading Volume

Related Companies and Tools


This page (LON:VRCI) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners